Betalucil is the trade name for metoprolol tartrate, which is effective in cardiac hypertrophy because of its clear inhibition of ventricular remodeling.
Betalucil, or metoprolol tartrate, is a beta-blocker commonly used in clinical practice. Its main effects include anti-heart failure, anti-arrhythmia, lowering blood pressure, and improving myocardial ischemia. Current research shows that beta-blockers have a clear effect on inhibiting ventricular remodeling, and cardiac hypertrophy is the pathological manifestation of ventricular remodeling, therefore, metoprolol tartrate is therapeutic for cardiac hypertrophy.
Metoprolol is contraindicated in patients with peripheral vasospastic disease, bradycardia, atrioventricular block, and bronchial asthma. In addition, beta-blockers have a significant rebound phenomenon, so you can not stop the drug without authorization, if there is fatigue, insomnia, mental depression and other uncomfortable symptoms, you need to pay attention to, and under the guidance of the doctor to adjust the medication.